Clinical bottom line
Clonal hematopoiesis of indeterminate potential (CHIP) is increasingly recognized not only as a precursor to hematologic malignancies but also as a significant contributor to cardiovascular disease (CVD) risk in patients with hematologic conditions. Emerging therapeutic strategies targeting the inflammatory and molecular pathways activated by CHIP mutations hold promise for mitigating cardiovascular complications in this population. While no agents are yet approved specifically for CHIP-driven CVD risk reduction, ongoing preclinical and early clinical investigations suggest that novel anti-inflammatory and targeted therapies may complement traditional cardiovascular risk management in hematology patients harboring CHIP. Clinicians should be aware of this evolving paradigm, balancing current evidence with individual patient risk profiles.
What the evidence shows
Clonal hematopoiesis refers to the expansion of blood cell clones carrying somatic mutations, commonly in genes such as DNMT3A, TET2, and ASXL1, without overt hematologic malignancy. CHIP prevalence increases with age and is associated with a higher risk of hematologic cancers (Warren et al., 2020). Importantly, CHIP has also been implicated in non-hematologic disorders, particularly cardiovascular disease, through pro-inflammatory mechanisms that exacerbate atherosclerosis and vascular dysfunction (Jaiswal et al., 2020).
Several studies have demonstrated that individuals with CHIP mutations have a significantly elevated risk of coronary artery disease, stroke, and heart failure compared to those without CHIP, independent of traditional cardiovascular risk factors (Conant et al., 2018; Jaiswal et al., 2020). The inflammatory milieu driven by mutant hematopoietic clones, including increased IL-1β and IL-6 signaling, contributes to endothelial injury and plaque instability.
Recent advances in modeling CHIP-driven cardiovascular pathology using self-organizing cardiac organoids have facilitated drug discovery efforts targeting these pathways (unattributed 2024). These models allow preclinical evaluation of candidate agents that may attenuate CHIP-associated inflammation and reduce cardiovascular risk.
Dietary interventions have also been proposed as adjunctive strategies to modulate inflammation and improve outcomes in patients with hematologic malignancies and CHIP (Brzechffa et al., 2026). Moreover, the recognition of CHIP’s role in cardiovascular risk has implications for risk stratification and management in hematology patients, especially those undergoing cytotoxic therapies or stem cell transplantation (Conant et al., 2018).
Caveats and uncertainty
Despite growing evidence linking CHIP to cardiovascular risk, the field remains in an early translational phase. Most data derive from observational cohorts and mechanistic studies rather than randomized controlled trials. The penetrance of CHIP mutations varies, and not all carriers develop cardiovascular complications, complicating risk prediction.
Therapeutic interventions specifically targeting CHIP-driven inflammation are largely experimental. While agents such as IL-1β inhibitors have shown cardiovascular benefit in broader populations, their efficacy and safety in CHIP-positive hematology patients require validation. The optimal timing, patient selection, and long-term outcomes of such therapies remain uncertain.
Additionally, the interplay between CHIP, hematologic disease progression, and cardiovascular risk is complex and bidirectional. Some hematologic treatments may influence clonal dynamics and cardiovascular risk, necessitating integrated management approaches.
Finally, the clinical utility of routine CHIP screening for cardiovascular risk stratification is not yet established, and guidelines do not currently recommend CHIP testing outside research settings.
How this may change practice
Awareness of CHIP as a modifiable cardiovascular risk factor in hematology patients may prompt clinicians to incorporate CHIP status into comprehensive risk assessments, particularly in older adults or those with unexplained cytopenias.
Pending further evidence, clinicians might consider more aggressive management of traditional cardiovascular risk factors in patients known or suspected to harbor CHIP. Participation in clinical trials investigating targeted anti-inflammatory or molecular therapies for CHIP-driven cardiovascular disease should be encouraged.
Multidisciplinary collaboration between hematologists, cardiologists, and researchers will be essential to translate emerging insights into practice. Future integration of CHIP testing into clinical workflows could enable personalized prevention strategies, but this awaits validation.
Nutritional and lifestyle interventions may offer low-risk adjunctive benefits and warrant consideration alongside pharmacologic approaches.